H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $55 from $49 and keeps a Buy rating on the shares. The firm says the low-dose NGN-401 data look impressive and better than TSHA-102. It is “cautiously optimistic “that there is a regulatory and development path forward for low-dose NGN-401.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio